IGLVVI-22-1

Across TCGA pan-cancer cohorts, IGLVVI-22-1 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated IGLVVI-22-1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher IGLVVI-22-1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated IGLVVI-22-1 expression acts as an unfavorable survival marker.

STAD, TGCT, and LUSC are the cancer types where IGLVVI-22-1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.196	0.593	<.001	108	view →
TGCT	OS	Tertile	All	0.672	0.991	<.001	108	view →
LUSC	OS	Tertile	All	0.131	0.766	<.001	108	view →
LIHC	DFS	Tertile	All	0.041	0.546	<.001	72	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
SARC	OS	Tertile	All	0.286	0.749	<.001	18	view →
COAD	OS	Tertile	III,IV	0.208	0.791	.008	9	view →
PRAD	DFS	Tertile	All	0.557	0.935	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

IGLVVI-22-1–STAD (OS)

Open the STAD breakdown →